Ryman Healthcare Limited logo

Ryman completes Retail Bookbuild, raising $902 million

Capital Raise9 March 2023RYMHealthcare

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES


10 March 2023


Ryman completes Retail Bookbuild, raising $902 million


Ryman is pleased to announce the successful completion of the shortfall bookbuild of

its Retail Entitlement Offer (Retail Bookbuild). The completion of the Retail

Bookbuild concludes the final stage of Ryman’s underwritten 1 for 2.81 accelerated

pro rata entitlement offer of new ordinary shares (the Offer) under which Ryman has

raised $902 million.


Summary of the Retail Bookbuild


Approximately 25 million New Shares, representing entitlements not taken up by

eligible retail shareholders and entitlements of ineligible retail shareholders in the

Retail Entitlement Offer, were offered for sale in the Retail Bookbuild.


The Retail Bookbuild was well supported, clearing at a price of $5.25 per New Share

(Bookbuild Price), which represents a premium of $0.25 (Premium) above the

offer price of $5.00 per New Share.


Additional Shares applied for by eligible retail shareholders in the Retail Entitlement

Offer will be allocated in full to those shareholders at the Bookbuild Price. Scaling has

been applied to institutional and broker bids in accordance with the terms set out in

the Offer Document dated 15 February 2023.


CEO Richard Umbers said, “We are very pleased with the level of support received

across both the retail and institutional components of our equity raising and to be able

to return a premium to shareholders who did not or could not participate. Proceeds

from the equity raising enable Ryman to be well positioned to execute its growth

framework and maintain the high standard of care it is known for”




Payment of Premium

Eligible retail shareholders who elected not to take up their entitlements and ineligible

retail shareholders will receive the Premium (less any applicable withholding tax) for

each New Share sold in the Retail Bookbuild.


The Retail Premium is expected to be paid to those retail shareholders on or about

Tuesday, 14 March 2023.


Allotment of New Shares


The settlement date for New Shares to be issued under the Retail Entitlement Offer

and the Retail Bookbuild is Tuesday, 14 March 2023. Those New Shares are also

expected to be allotted and issued to commence trading on Tuesday, 14 March 2023.


All New Shares issued under the Retail Entitlement Offer and the Retail Bookbuild will

rank equally with Ryman’s existing ordinary shares.


Repayment of tranche 1 of the USPP Notes


As disclosed in the investor presentation dated 15 February 2023, Ryman will repay

the USPP Notes and associated costs in full using proceeds from the equity raise. The

first tranche of USPP Notes and associated costs will be repaid today, with the

remaining USPP Notes and associated costs expected to be repaid on or around

Friday, 24 March 2023.





About Ryman:

Ryman Healthcare was founded in Christchurch in 1984 and owns and operates 45

retirement villages in New Zealand and Australia. Ryman villages are home to

approximately 13,700 residents, and the company employs approximately 6,800 staff.


Contacts:


Investor queries:


Hayden Strickett, Head of Investor Relations,

+64 27 303 1132 or hayden.strickett@rymanhealthcare.com


Media queries: Marsha Cadman, Chief Sales and Marketing Officer

+61 414 790 480 or marsha.cadman@rymanhealthcare.com






Important Notice

This communication is not for distribution or release in the United States. This communication

does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the

United States. The entitlements and the New Shares have not been, and will not be, registered

under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or the securities laws

of any state or other jurisdiction of the United States, and may not be offered or sold, directly

or indirectly, in the United States or to any person acting for the account or benefit of any

person in the United States (to the extent such person is acting for the account or benefit of a

person in the United States).

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.